BLASUBCUTANEOUSSOLUTION
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
TRESIBA (insulin degludec) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2015.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRESIBA (insulin degludec) is a long-acting basal insulin analog administered subcutaneously for the treatment of diabetes mellitus. It is designed to provide steady, prolonged insulin coverage with a ultra-long duration of action, reducing the frequency of injections compared to earlier insulin formulations. TRESIBA serves as a foundational basal insulin therapy in type 1 and type 2 diabetes management.
$28MPart D
PeakTRESIBA is at peak lifecycle maturity with modest Part D penetration, suggesting a stable but not high-growth commercial environment with potential for selective specialty care focus.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
Started Dec 2023
227 enrolled
Diabetes Mellitus, Type 1
A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level
Started Nov 2023
179 enrolled
Diabetes Mellitus, Type 2
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
Started Jul 2023
414 enrolled
Diabetes
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
Started Aug 2022
692 enrolled
Type 1 DiabetesDiabetes
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
Started Jul 2022
0Diabetes Mellitus, Type 2
Worked on TRESIBA at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.